References: | Seargent, J. M., Yates, E. A., & Gill, J. H. (2004). GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation.British journal of pharmacology,143(8), 933-937. Collino, M., Patel, N. S., Lawrence, K. M., Collin, M., Latchman, D. S., Yaqoob, M. M., & Thiemermann, C. (2005). The selective PPARγ antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion.Kidney international,68(2), 529-536. Wojtowicz, A. K., Szychowski, K. A., & Kajta, M. (2014). PPAR-γ agonist GW1929 but not antagonist GW9662 reduces TBBPA-induced neurotoxicity in primary neocortical cells.Neurotoxicity research,25(3), 311-322. |